CTIS2024-512019-36-00进行中（未招募）1 期
LION-1
niversitaetsklinikum Wuerzburg AöR0 个研究点目标入组 46 人开始时间: 2024年6月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
尚未招募
2 期
Effects of exercise program on fall risk reduction in pre-frail older adultspre-frailProgram exercise,Risk of fall,TCTR20180806001Faculty of Medicine Chiang Mai University72
进行中（未招募）
1 期
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasarge Granular Lymphocytic Leukemia or Cytotoxic LymphomasMedDRA version: 20.0Level: LLTClassification code: 10029430Term: NK-cell leukemia Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065862Term: T-cell large granular lymphocytic leukemia Class: 10029104CTIS2023-503550-13-00Dren Bio Inc.116
进行中（未招募）
1 期
A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus ErythematosusCTIS2023-508236-60-00Autolus Limited12
招募中
1 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid TumorsCTIS2023-505576-29-00Centessa Pharmaceuticals UK Limited180
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOADCTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59